TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33371905
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion)
Study: 33371905
Drug: Standard-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion)
Study: 33371905
Drug: Standard-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cholecalciferol
Study: 34954857
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d
Study: 34181084
Drug: Systemic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia (S) with 1 gram of paracetamol and 2 mg/kg ketoprofen administered IV after skin closure
Study: 33486139
Drug: Apomorphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine infusion (APO)
Study: 616775801
Drug: GDF-15 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF-15 group 1 (<1,200 ng/L)
Study: 616775801
Drug: GDF-15 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF-15 group 3 (>1,800 ng/L)
Study: 36370185
Drug: Prolonged prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged prophylactic antibiotic therapy (PAT) group (Group B)
Study: 36370185
Drug: No prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prolonged prophylactic antibiotic therapy group (Group A)
Study: 35662546
Drug: CO2 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 vaginal laser treatment
Study: 32036258
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine + 5 μg dexmedetomidine (Group D)
Study: 32051317
Drug: Platelet rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet rich plasma (PRP) injection
Study: 35279741
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with apremilast and narrowband UVB
Study: 35279741
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB monotherapy
Study: 35677371
Drug: Orthodontics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontics plus implant anchorage
Study: 36273083
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (cholecalciferol) supplementation, weekly for six weeks
Study: 32200813
Drug: Ranibizumab monthly
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monthly treatment
Study: 32200813
Drug: Bevacizumab monthly
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab monthly treatment
Study: 32200813
Drug: Monthly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly treatment
Study: 32200813
Drug: As-needed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed treatment
Study: 32200813
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from monthly to as-needed treatment
Study: 33220115
Drug: Training stop‐smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training stop‐smoking practitioners to deliver support according to the NCSCT Standard Treatment Programme
Study: 34620774
Drug: Social media-based
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social media-based community consultation (CC) using Facebook and Instagram advertisements
Study: 32669234
Drug: Daily digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily digital media activity
Study: 33886115
Drug: Single antibiotic
Normalized name: BACITRACIN ZINC 500 [iU] in 1 g TOPICAL OINTMENT [Single Antibiotic]
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single antibiotic
Study: 32841892
Drug: Low-intensity interventions
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity interventions for individuals with low interpersonal risks and concurrent protective psychological factors
Study: 32609084
Drug: Progesterone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (400 mg vaginal suppositories, twice daily)
Study: 32609084
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched vaginal suppositories)
Study: 32782170
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) for 3 months before IVF
Study: 33107418
Drug: Δ9‐THC (1.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ9‐THC (1.19 mg/2 ml)
Study: 36502500
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% hexylresorcinol
Study: 36502500
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% hydroquinone
Study: 34418415
Drug: Lung ultrasound-guided
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ultrasound-guided treatment strategy
Study: 32962735
Drug: Mannose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannose supplementation at a total of 1-2 g mannose/kg b.w./d divided into 5 single doses
Study: 34083403
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg daily for 3 days followed by 250 mg daily for 12 days + Hydroxychloroquine 200 mg twice daily for 15 days
Study: 32638409
Drug: Fasting proinsulin
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting proinsulin to insulin ratio
Study: 33783846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hypnosis and TENS
Study: 32844813
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants (Type 1 ITI protocol)
Study: 32844813
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants (Type 4 ITI protocol)
Study: 34421796
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of GTN (5 mg GTN in 50 ml saline at a rate of 0.4 mg/h for 12.5 h/day for 2 days)
Study: 34421796
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.9% normal saline (NS) (total 50 ml/day at 4 ml/h for 12.5 h/day for 2 days)
Study: 33256841
Drug: Immunosuppressants in
Normalized name: Other immunosuppressants in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants in AS cohort
Study: 35684140
Drug: High-dose eggshell
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose eggshell membrane
Study: 35684140
Drug: Low-dose eggshell
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose eggshell membrane
Study: 34047177
Drug: 6TG added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6TG added to MTX/6MP maintenance therapy
Study: 35659172
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy (PDC)
Study: 34138468
Drug: IVIG (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (25 g/day for three days)
Study: 32865577
Drug: Tele-BA (behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-BA (behavioral activation) treatment delivered by lay counselors
Study: 32865577
Drug: Tele-PST (problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-PST (problem-solving therapy) delivered by licensed clinicians
Study: 34602412
Drug: Capsule Picolin
Normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Picolin (500 mg, two capsules thrice a day)
Study: 34602412
Drug: Tablet Picolin-E
Normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Picolin-E (250 mg, thrice a day)
Study: 34602412
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, twice a day)
Study: 34602412
Drug: Capsule Picolin
Normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Picolin
Study: 34602412
Drug: Tablet Picolin-E
Normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Picolin-E
Study: 35439983
Drug: Nomogram incorporating
Normalized name: Liposome-incorporated DTP-GDP
DrugBank: Liposomal N-acetylglucosminyl-N-acetylmuramly-L-Ala-D-isoGln-L-Ala-gylceroldipalmitoyl (DB17316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram incorporating independent prognostic factors (age, AJCC 8th edition T, N and M stage, carcinoembryonic antigen (CEA), tumour differentiation, chemotherapy, perineural invasion, LNR)
Study: 36307314
Drug: Qili Qiangxin
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qili Qiangxin Capsule combined with cardiac exercise rehabilitation
Study: 34443468
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with hydrolyzed fish cartilage for 90 days
Study: 35427193
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control group (n = 114)
Study: 34304292
Drug: Home-based strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based strength exercise (twice weekly for 10 weeks)
Study: 32770612
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus gabapentin titrated to drug tolerance during radiation
Study: 34469765
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination strategy (including at least two blood pressure lowering agents plus a statin, with or without aspirin)
Study: 34469765
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination strategy (with aspirin)
Study: 34469765
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination strategy (without aspirin)
Study: 34469765
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination strategy
Study: 34469765
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination strategy with aspirin
Study: 34469765
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination treatment
Study: 34521398
Drug: Curcumin nanomicelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin nanomicelle capsules 80 mg twice a day for 7 weeks
Study: 32101271
Drug: Olanzapine and
Normalized name: olanzapine and samidorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine and sertraline
Study: 32101271
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and sertraline
Study: 34996948
Drug: MCALP group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCALP group: 0.5 g of methylprednisolone intravenously for three consecutive days at the beginning of the course and 3rd month, oral prednisone at a dose of 15 mg every other day for 6 months
Study: 34996948
Drug: FP group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP group: 0.8-1.0 mg/kg/days of prednisone (maximum 70 mg/day) for 2 months, then tapered by 5 mg every 10 days for the next 4 months
Study: 32819927
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 (1 mg/day in weeks 1-8, 1 mg/week in weeks 9-52)
Study: 32819927
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin B12 (1 mg on alternate days in weeks 1-2, 1 mg/week in weeks 3-8, 1 mg/month in weeks 9-52)
Study: 32819927
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12
Study: 32819927
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin B12
Study: 34626927
Drug: LB 266
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LB 266 mg TAP block alone
Study: 34626927
Drug: ITM 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITM 50 μg followed by LB 266 mg TAP block
Study: 34626927
Drug: ITM 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITM 150 μg alone
Study: 34626927
Drug: LB 266
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LB 266 mg TAP block alone and LB + ITM group
Study: 33248594
Drug: HL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL group (high-low Zn, basal diets supplemented 120 mg/kg Zn)
Study: 33248594
Drug: LH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH group (low-high Zn, basal diets supplemented 120 mg/kg Zn)
Study: 34282267
Drug: Mecobalamin intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamin intramuscular injections (0.5 mg/day, 3 times/week)
Study: 34282267
Drug: Mecobalamin oral
Normalized name: mecobalamin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamin oral tablets (1.5 mg/day)
Study: 36432469
Drug: P-CHO (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-CHO (20 g of Pronativ®, native whey protein and 60 g of carbohydrate)
Study: 36432469
Drug: CHO (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (80 g of carbohydrate)
Study: 33691305
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug classes
Study: 32469384
Drug: Savolitinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib (600 mg orally once daily)
Study: 32469384
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks without treatment)
Study: 32243609
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg daily oral iron
Study: 35811090
Drug: Vestibular socket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular socket therapy (VST) (test; n=20)
Study: 35811090
Drug: Contour augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contour augmentation (control; n=20)
Study: 32476816
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears and 0.1% fluorometholone eye drops three times a day (G-DESOS group)
Study: 33273644
Drug: Sufentanyl target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanyl target infusion based on the pupillary pain index
Study: 33273644
Drug: Standard sufentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sufentanyl target infusion left to the discretion of the anesthesiologist (Control)
Study: 34083348
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (home-based exercise, weekly telephone support, breathlessness management leaflet) with either placebo or active NMES for 6 weeks
Study: 32588429
Drug: Non-platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based chemotherapy (non-PBC)
Study: 32588429
Drug: PBC in
Normalized name: Brovex PBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBC in first-line therapy
Study: 34717535
Drug: Paracetamol 1 g
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1 g (P group)
Study: 34717535
Drug: Dexamethasone 8 mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8 mg IVI (D group)
Study: 32964807
Drug: Docking studies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docking studies (new designed compound C2)
Study: 33956703
Drug: Pramipexole (n=31),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (n=31), initiated at 0.125 mg 2 times a day, increased to a target of 4.5 mg/d
Study: 34726501
Drug: Banaba (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banaba (500 mg) twice a day for 12 weeks
Study: 35553855
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained daily lifestyle without training)
Study: 32418078
Drug: Adjuvant transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant transarterial infusion chemotherapy (TAI) with FOLFOX regimen
Study: 32418078
Drug: Follow-up without
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up without any adjuvant treatment (FU group)
Study: 36573717
Drug: Glimepiride treatment
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride treatment
Study: 32107337
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2) given concurrently prior to each infusional EPOCH cycle
Study: 32107337
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2) given sequentially (weekly for 6 weeks) following completion of EPOCH
Study: 32107337
Drug: EPOCH chemotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH chemotherapy (96-hour IV infusion of etoposide, doxorubicin, vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles)
Study: 32713846
Drug: Colonoscopy (CC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopy (CC), n=346
Study: 32713846
Drug: Capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule endoscopy (CE), n=305
Study: 33399050
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (RT) with Gloreha device
Study: 36124455
Drug: Acupotomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupotomy treatment on pain points around knee joint, once a week for 3 weeks.
Study: 36124455
Drug: Celecoxib capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib capsule, 200 mg orally once a day for 3 weeks (western medicine group).
Study: 33236043
Drug: Peanut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut group (56 g/d as snacks, n=113)
Study: 34085476
Drug: Valaciclovir hydrochloride
Normalized name: Valaciclovir hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir hydrochloride tablets, mecobalamin tablets, and vitamin B1 tablets
Study: 34738660
Drug: Romosozumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (210 mg sc monthly, n = 17)
Study: 34738660
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg sc daily, n = 19)
Study: 34738660
Drug: Placebo (sc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sc monthly, n = 20)
Study: 35645797
Drug: Fosaprepitant (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant (150 mg)
Study: 35645797
Drug: Palonosetron (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (75 μg)
Study: 32797298
Drug: rt-PA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (intravenous recombinant tissue-plasminogen activator)
Study: 34351478
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase
Study: 33729386
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with batroxobin
Study: 32854478
Drug: miR‐146a‐3p inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: miR‐146a‐3p inhibitor group
Study: 32854478
Drug: sh‐KCNQ1OT1+miR‐146a‐3p inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: sh‐KCNQ1OT1+miR‐146a‐3p inhibitor group
Study: 32208848
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice (200-500 mL/day)
Study: 32208848
Drug: Resveratrol (150-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (150-1000 mg/day)
Study: 34279759
Drug: Group Cognitive-Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioral Intervention (Healthy Minds) consisting of eight sessions based on cognitive behavioral therapy principles and techniques.
Study: 33599062
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections every month for a maximum of two sessions
Study: 33940637
Drug: Fast needle
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast needle acceleration (higher than 1 g)
Study: 33940637
Drug: Slow needle
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow needle acceleration (lower than 1 g)
Study: 33448941
Drug: Air-Fluidized Therapy
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-Fluidized Therapy (AFT)
Study: 36909343
Drug: Prebiotic supplement
Normalized name: FlorastorSelect Gut Boost Daily Probiotic and Prebiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplement
Study: 35710539
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication reduction
Study: 34101780
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1.2 mg/d + vitamin B12 50 μg/d